sitemapHome | Registration | Job Portal for CA's | Expert Exchange | Currency Converter | Post Matrimonial Ads | Post Property Ads
News shortcuts: From the Courts | News Headlines | VAT (Value Added Tax) | Placements & Empanelment | Various Acts & Rules | Latest Circulars | New Forms | Forex | Auditing | Direct Tax | Customs and Excise | ICAI | Corporate Law | Markets | Students | General | Mergers and Acquisitions | Continuing Prof. Edu. | Budget Extravaganza | Transfer Pricing | GST - Goods and Services Tax
Latest Expert Exchange
News Headlines »
 Companies (Appointment and Qualification of Directors) Sixth Amendment Rules, 2018.
 Easier tax refund regime for exporters in the works
 Income tax on your gold and real estate investments
 Extension of time limit for submitting the declaration in FORM GST TRAN-1 under rule 117(1A) of the Central Goods and Service Tax Rules, 2017 in certain cases
 How RBI dealt with the crisis amid tensions with FinMin
 Pay tax on this PF account withdrawal Income tax return (ITR) filinga
 Seeks to make amendments (Ninth Amendment, 2018) to the CGST Rules, 2017.
 How govt is dealing with tax evasion, corporate fraud
 How to check income tax return (ITR) status
 Second instalment of advance tax due on 15 September
 Missed the deadline for filing India ITR? Here is what you can do

Pharma sector mulls alternative tax incentive package
January, 09th 2007

The pharma industry on Tuesday will propose a package of tax incentives that the Union Finance Minister, Mr P. Chidambaram, could consider to encourage research and development (R&D) spend.

This package is an alternative for the Minister to consider if the industry's existing demand of extending the 150 per cent weighted tax deduction on R&D spend by 10 more years does not find favour with the Government.

Pharma industry captains are expected to meet Mr Chidambaram on Tuesday as part of the pre-budget consultations with the industry.

Alternative package

The alternative package comprises 100 per cent deduction on R&D revenue expenditure incurred for the business of the assessee. This should cover direct expenditure, sponsored research and contribution made to approved institutions.

As part of the package, the pharma industry is set to suggest an accelerated depreciation of 100 per cent on R&D capital expenditure including cost of building.

It also wants tax credit to be fixed at the rate of 20 per cent on total R&D revenue expenditure incurred during the year, with the unused credit allowed to be carried forward for 15 years.

Pharma and biotech industry are by far the highest spenders on R&D, together accounting for Rs 2,000 crore, say industry leaders. They claim that this figure was twice as much as what the auto industry spends and four times as much as the IT industry spends on R&D.

Sources said that industry will also seek tax exemptions under the Sections 10A and 10B of the Income-Tax Law to be extended to biotechnology, healthcare, R&D and clinical trial activities.

Home | About Us | Terms and Conditions | Contact Us
Copyright 2018 CAinINDIA All Right Reserved.
Designed and Developed by Binarysoft Technologies Pvt. Ltd.
Article Management Solutions System Article Management Software S

Transfer Pricing | International Taxation | Business Consulting | Corporate Compliance and Consulting | Assurance and Risk Advisory | Indirect Taxes | Direct Taxes | Transaction Advisory | Regular Compliance and Reporting | Tax Assessments | International Taxation Advisory | Capital Structuring | Withholding tax advisory | Expatriate Tax Reporting | Litigation | Badges | Club Badges | Seals | Military Insignias | Emblems | Family Crest | Software Development India | Software Development Company | SEO Company | Web Application Development | MLM Software | MLM Solutions